4D Molecular Therapeutics, Inc. (FDMT)
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $85.2M
- Net income
- -$140.1M
- Total assets
- $566.7M
- Market cap
- $451.7M
- Operating margin
- -187.2%
- Net margin
- -164.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $85.2M
- Operating expenses
- $244.8M
- Operating income
- -$159.5M
- Income tax
- $0
- Net income
- -$140.1M
- EPS (basic)
- $-2.42
- EPS (diluted)
- $-2.42
Balance sheet
- Total assets
- $566.7M
- Current assets
- $413.1M
- Total liabilities
- $61.0M
- Current liabilities
- $44.0M
- Shareholders’ equity
- $505.7M
Cash flow
- Operating cash flow
- -$109.1M
- Investing cash flow
- -$93.0M
- Financing cash flow
- $113.0M
- Net cash flow
- -$89.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $451.7M
- EPS (diluted)
- $-2.42
- Shares outstanding
- 44.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 11, 2020
4D Molecular Therapeutics, Inc. (FDMT) Stock Price
- Reported a net loss of $140.1M in FY2025.
- Revenue grew 372% from FY2021 to FY2025.
- Trading 24% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review 4D Molecular Therapeutics, Inc..
Write a review
News about 4D Molecular Therapeutics, Inc.
News & sentiment via Polygon.io
4D Molecular Therapeutics, Inc.: frequently asked questions
Is 4D Molecular Therapeutics, Inc. an American company?
4D Molecular Therapeutics, Inc. is a US-based company headquartered in Emeryville, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is 4D Molecular Therapeutics, Inc. headquartered?
4D Molecular Therapeutics, Inc. is headquartered in Emeryville, California, United States.
Is 4D Molecular Therapeutics, Inc. publicly traded?
Yes — 4D Molecular Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol FDMT on the NASDAQ.
What does 4D Molecular Therapeutics, Inc. do?
4D Molecular Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
